Eli Lilly and Company Confident R&D Spending Will Pay Off

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

"I think that we're beginning to see the light at the end of the tunnel here," Eli Lilly CEO John Lechleiter tells WSJ regarding the payoff for what the Journal calls, a "relatively hefty R&D budget." Patent expirations for Zyprexa, Cymbalta, and Evista have hit revenue and the company is now betting on ramucirumab (in gastric cancer) and a once-a-day diabetes pill, as its R&D spend has ballooned to $5.3B, or 23% of revenue.

Help employers find you! Check out all the jobs and post your resume.

Back to news